Could a common heart drug protect HIV patients from heart failure?
NCT ID NCT04153136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called sacubitril-valsartan (Entresto) can improve early signs of heart failure in people with HIV. The 39 participants had well-controlled HIV but showed subtle heart changes on scans. The goal was to see if the drug could reduce inflammation and improve heart function, potentially preventing full-blown heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacubitril-Valsartan (Entresto)
- What this could lead to
- If successful, this could point toward a way to prevent or slow heart failure in people with HIV.
- What could go wrong
- This is a small, early-phase study with only 39 participants. It may not show clear benefits, and the drug can cause side effects like low blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can shedding pounds reboot the Heart's exercise engine?
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a robot help stroke survivors with HIV walk again?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Can a Father-Focused program curb HIV, substance abuse, and violence?